Lipocine Inc.
Lipocine Inc. (Nasdaq: LPCN) is a biopharmaceutical company developing oral medicines using proprietary drug-delivery technology designed to improve absorption of drugs that are difficult to deliver orally. Its portfolio addresses hormone supplementation, neurological and psychiatric disorders, liver disease, and… From the company’s description.
Over the twelve months to Sep 30, 2026, Lipocine Inc. reported revenue of $3.75M, down 13.3% from a year earlier, and a net loss of $9.33M. Its operating margin was −269.0%, and operations used $10.01M in cash. In fiscal 2025, it reported revenue of $1.98M, down 82.3% from fiscal 2024, and a net loss of $9.63M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Lipocine Inc. does
In the company’s own words
Lipocine Inc. (Nasdaq: LPCN) is a biopharmaceutical company developing oral medicines using proprietary drug-delivery technology designed to improve absorption of drugs that are difficult to deliver orally. Its portfolio addresses hormone supplementation, neurological and psychiatric disorders, liver disease, and obesity management. The FDA-approved product TLANDO is an oral testosterone replacement therapy for adult men with testosterone deficiency; Lipocine licenses commercialization rights to partners in the United States and Canada, South Korea, Gulf Cooperation Council countries, and Brazil, and retains rights in other territories. Its clinical pipeline includes LPCN 1154, an oral brexanolone candidate for postpartum depression, as well as candidates for major depressive disorder, epilepsy, and essential tremor. Other assets include candidates for cirrhosis management, obesity-related body composition, and prevention of recurrent preterm birth. Lipocine earns revenue potential through license fees, milestones, royalties, and product supply arrangements with commercial partners, while continuing development of its pipeline and seeking additional partnerships.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SALT LAKE CITY, X1
- Fiscal year end
- December
- CIK
- 1535955
- SIC
- 2834
Financial performance, year by year
Fiscal 2012–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Lipocine Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Lipocine Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Lipocine Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Lipocine Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Lipocine Inc.'s last four quarterly filings that the numbers alone won't show?”